LONDON, ON, Dec. 21, 2017 /CNW/ - Starting January 1st, 2018, under the new OHIP+ program, the Ontario Drug Benefit Program will cover AeroChamber Plus® Flow-Vu® antistatic chambers for children 12 years of age and under. Children prescribed a Metered Dose Inhaler (MDI) for their asthma will now be eligible for one (1) chamber per year under this new program. A prescription must be provided by a doctor or Nurse Practitioner in order to be eligible for reimbursement.
About AeroChamber Plus® Flow-Vu® Chambers:
- #1 recommended chamber by pharmacists and doctors in Canada1.
- Validated with safety and efficacy studies in numerous third party clinical evaluations amongst various patient populations and it is the chamber most recommended by leading MDI pharmaceutical companies2
- Antistatic chamber designed to deliver the intended prescribed dose via the MDI, similar to using an MDI with perfect technique3
- The only chamber with the Flow-Vu® inhalation indicator for the care-giver to observe effective inhalation. The Flow-Vu® indicator provides real time feedback confirming an effective inhalation and ensures that there are no leakages of ambient air into the space between facemask and face, that could prevent medication delivery altogether. www.aerochamber.com
For Dose Assurance and Improved Clinical Outcomes
A landmark real-world study in more than 18,000 patients has demonstrated superior asthma control with the AeroChamber Plus® Flow-Vu® antistatic Valved Holding Chamber (VHC, or spacer) compared with other chamber devices.4 For those with asthma, particularly children, the choice of device to deliver their medication is an important consideration; even with the same metered-dose inhaler (MDI), not all valved holding chambers perform equally well.5 According to the study, published in Pulmonary Therapy, the AeroChamber Plus* Flow-Vu* antistatic chamber was associated with delayed time to first exacerbation, fewer asthma related emergency department visits, and lower exacerbation-related costs than control chambers.
- It has been reported that patients who use a MDI and chamber have better asthma control.6 Chambers were designed to reduce the oropharyngeal deposition by changing the particle size distribution of the inhaled aerosol, and by holding the aerosol in the chamber until the patient is ready to inhale, which reduces the need for good coordination between inhalation and inhaler actuation.7 Effectiveness of these devices can be adversely affected by the design, including the chamber electrostatic charge, a commonly reported cause of inconsistent medication delivery.8
- Canadian Paediatric Society and the Canadian Thoracic Society joint statement on Asthma recommend that Inhaled Corticosteroids (ICS) are to be administered by metered-dose inhaler with an age-appropriate valved spacer [chamber]9
- The Lung Association has endorsed our product with the following statement: The Lung Association believes that using the AeroChamber Plus® Flow-Vu® VHC with your metered dose inhaler helps to ensure medication is delivered to where it is needed in your lungs.
About Trudell Medical International (TMI)
Trudell Medical International is a global manufacturer located in London, Ontario and our products are sold in over 110 countries. We design, develop, manufacture, and distribute from our London head office which is also home to a Global Aerosol Lab and Research Center. www.trudellmed.com
® trade-marks and registered trade-marks of Trudell Medical International © TMI 2017. All rights reserved.
1 #1 Brand based on independent survey of Pharmacists and Physicians.
2 Study Summary: AeroChamber® Brand of VHC, May 2016.
3 Harkness H et al. Valved Holding Chambers are non-interchangeable: Development of a Universal VHC that provides assurance of drug delivery to patients and health care providers. Presented at Canadian Respiratory Conference, 2012.
4 Burudpakdee C, Kushnarev V, Coppolo D, Suggett J. A retrospective study of the effectiveness of the AeroChamber Plus® Flow-Vu® Antistatic Valved Holding Chamber for asthma control. Pulmonary Therapy. 2017. https://doi.org/10.1007/s41030-017-0047-1. Accessed July 14.
5 Nagel MW, Suggett JA. Equivalence evaluation of valved holding chambers (VHCs) with albuterol pressurized metered dose inhaler (pMDI). Respiratory Drug Delivery Europe; April 25-28, 2017, 2017; Nice, France.
6 Levy ML, et al. Asthma patient's inability to use a pressurized metered-dose inhaler (pMDI) correctly correlates with poor asthma control as defined by the Global Initiative for Asthma (GINA) strategy: a retrospective analysis. Prim Care Respir J. 2013; 22(4):406-11
7 Lavorini F, Fontana GA. Targeting drugs to the airways: The role of spacer devices. Expert opinion on drug delivery. 2009;6(1):91-102.
8 Mitchell JP, Coppolo DP, Nagel MW. Electrostatics and inhaled medications: influence on delivery via pressurized metered-dose inhalers and add-on devices. Respiratory care. 2007;52(3):283-300.
9 Ducharme, FM et al. Diagnosis and management of asthma in preschoolers: A Canadian Thoracic Society and Canadian Paediatric Society position paper. Can Respir J 2015;22(3): 135-143
SOURCE Trudell Medical International
For further information: For clinical inquiries, please contact: Jason Suggett PhD, BPharm, MBA, MRPharmS, Group Director of Global Science and Technology